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Abstract 
The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-
ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-
(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the 
thioether, showed the lowest IC50 values in enzymatic assays (10-206 nM), the most potent 
compounds 4d-4h (IC50 10-28 nM) bearing hydrophobic groups (Me, F, CF3 and Cl) in the terminal 
phenyl ring.  A convincing rationalization was achieved for the highest potent compounds 4 as type 
II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the 
arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical 
Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and 
tube formation were observed at low concentrations. These compounds have also shown to increase 
apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 
was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited 
at 1.0 and 2.5 M for the most promising compounds. Altogether, these findings point to an 
antiangiogenic effect in HUVECs.  
 
Keywords: Thienopyridinethioether 1,3-diarylureas; VEGFR-2 tyrosine kinase inhibitors; Enzymatic 
assays; Molecular Docking; HUVECs; Antiangiogenesis assays, Western blotting 
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 1. Introduction 
The Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) is a class V Receptor Tyrosine 
Kinase (RTK), expressed primarily in endothelial cells, and is activated by the specific binding of 
Vascular Endothelial Growth Factor (VEGF), secreted by endothelial cells and various tumor cells, 
to the VEGFR-2 extracellular regulatory domain. Once activated, VEGFR-2 undergoes 
autophosphorylation, triggering signalling pathways leading to endothelial cell proliferation and 
subsequent tumor angiogenesis that promotes tumor growth and metastasis.
1
 Several small-molecule 
VEGFR-2 inhibitors have emerged as promising antiangiogenic agents for treatment against a wide 
variety of cancers and act by competing with adenosine triphosphate (ATP) for the ATP-binding site 
of the VEGFR-2 intracellular kinase domain, thereby preventing the intracellular signalling. This 
leads to angiogenesis,
2
 the sprouting of new capillaries from pre-existing blood vessels, which is a 
multistep process involving endothelial cell differentiation, proliferation, migration, permeability 
and tube formation. These assays are used to reproduce the angiogenesis process in vitro.
3
  
Most known kinase inhibitors are classified as type I kinase inhibitors, which bind in and around the 
region occupied by the adenine ring of ATP.
4 
Sunitinib is a classical example of a type I inhibitor and 
has been approved for the treatment of renal cell carcinomas and gastrointestinal stromal tumors.
5 
On the other hand, type II kinase inhibitors induce the inactive DFG-out conformation of the 
activation loop, enabling them to occupy the adenine binding site and an adjacent hydrophobic 
pocket created by this rearrangement. As the residues forming the hydrophobic pocket are less 
conserved than residues in the adenine pocket, type II inhibitors usually provide a better kinase 
selectivity when compared to type I inhibitors.
4, 6 
For VEGFR-2, several type II inhibitors have been reported. These inhibitors occupy the adenine 
pocket with a suitable ring or ring system that is able to promote 1 to 3 H-bonds with the kinase 
hinge region (Glu917-Cys919); while also occupying the hydrophobic pocket that is available in the 
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DFG-out conformation (Asp1046-Phe1047-Gly1048 for VEGFR-2), with a suitable ring or ring 
system. A pair of hydrogen bond donating and accepting groups, (usually an urea or a corresponding 
bioisosteric core) is also present to establish H-bonds with Asp1046 and Glu885. The ring systems 
occupying both the adenine and the hydrophobic pocket are usually linked via a central ring 
positioned in an intermediate linker region (Figure 1 and 2).  
A number of type II VEGFR-2 inhibitors, relevant for the discussion of the results are presented in 
figure 1. They present a typical pharmacophore model for these inhibitors where a central aryl ring, 
occupying the linker region, is bound to the ring occupying the adenine pocket via an ether linker 
(O-linker), while the ring in the hydrophobic pocket is bound to the central ring via an urea group in 
para position to the O-linker. In the course of molecular modelling studies performed in our group 
and following a previous study presenting thieno[3,2-d]pyrimidines as VEGFR-2 inhibitors,
 
several 
observations suggested that alternatives to the O-linker using different configuration patterns, could 
be explored in an attempt to synthesize original VEGFR-2 inhibitors.
10 
Specifically the use of a 
thioether linker (S-linker) instead of an ether linker (O-linker) could provide interesting compounds 
with potent VEGFR-2 inhibition capability and with an alternative profile to the existent type II 
VEGFR-2 inhibitor scaffolds. Sorafenib was used for comparison with compounds that present 
similar substituents in the terminal aryl ring located in the hydrophobic pocket. 
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Figure 1. VEGFR-2 type II inhibitors presenting an O-linker in the para position relative to the urea 
moiety: Sorafenib (Nexavar®, Bayer, Germany; IC50 = 90 nM),
7
 A (TSK/Tsukuba IC50 = 3.5 nM)
8
 
and B (pyrrolo[3,2-d]pyrimidine derivative; IC50 = 6.2 nM).
9
 
 
Herein, we describe an on-going effort to develop novel small-molecule VEGFR-2 inhibitors, based 
on the thieno[3,2-b]pyridine-7-thioether-1,3-diarylurea scaffold. The synthesis and the VEGFR-2 
enzymatic inhibition activity assays of a novel series of 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-
ylthio)phenyl]ureas are presented. Docking simulations were performed to analyze the binding mode 
of the more potent synthetized compounds. The best compounds identified in enzymatic assays were 
then tested in VEGF-stimulated Human Umbilical Vein Endothelial Cells (HUVECs). Their 
proliferation, apoptosis, migration and tube formation, VEGFR-2 expression and activity were 
examined by BrdU, TUNEL, wound healing and matrigel assays, and by Western blot, respectively.   
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2. Results and Discussion 
2.1. Synthesis 
The 7-chlorothieno[3,2-b]pyridine 1,
11a,b
 obtained from the commercial 7-hydroxythieno[3,2-
b]pyridine and POCl3, reacted with 2- 3- or 4-aminothiophenol in stoichiometric amounts in DMF at 
140 ºC for 2h to give only the aminated di(hetero)arylthioethers 2a-c by nucleophilic aromatic 
substitution, in very good yields (Scheme 1). These were reacted with differently substituted 
arylisocyanates in THF/CH2Cl2 at room temperature for 12 h, to give the 1-aryl-3-[2-, 3- or 4-
(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3a-c, 4a-h and 5a-e in good yields (Scheme 1). The 
synthesis of compounds 4d-h bearing hydrophobic groups, was performed after the best results 
obtained in enzymatic assays (Table 1) for the substitution pattern of compounds 4a-4c. For the 
compounds 5, based also in the results of enzymatic assays (Table 1) that were not so good then for 
series 4, only compounds with substituents that are present in Sorafenib (Figure 1) CF3 and/or Cl, 
were prepared in order to evaluate their effects. 
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Scheme 1. Synthesis of the 2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)anilines 2a-c and of the 1-aryl-
3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3-5. 
 
2.2. Enzymatic Inhibition and Structure Activity-Relationship 
 
Compounds 3a-c, 4a-c and 5a-c were first synthetized and subsequently evaluated for their ability to 
interact with the VEGFR-2 kinase domain (Table 1), using an enzymatic FRET-based assay.
12
 The 
three series differ in the position of the arylurea scaffold; with compounds 3, 4 and 5 bearing it in 
the ortho, meta and para-position relative to the thioether linker, respectively. Compounds 4a-c 
displayed the highest enzyme inhibition potency with IC50 values of  94, 107 and 206 nM, 
respectively; whereas compounds 5a , 5b displayed either moderate, 1160 and 1390 nM, 
respectively, or 5c weak VEGFR-2 inhibition activity, 8360 nM; compounds 3a-c were inactive. 
These findings are surprising as compounds 5 present similarities with known VEGFR-2 inhibitors 
with the arylurea moiety in the para position,
8-10, 13-15
 including the drug Sorafenib
 
(Figure 1).
7
 
Instead, compounds 4a-4c with the arylurea group in the meta position, were an order of magnitude 
more potent. The arylurea in the meta position is usually not considered as a promising feature and 
the studies using different scaffolds as potential VEGFR-2 inhibitors always explore the arylurea in 
the para position 
7-10, 13-15
 although presenting an O-linker instead of a S-linker.   
In fact, considering the number of scaffolds with VEGFR-2 inhibitory activity already published, it 
is surprising that a S-linker in meta position relative to the urea moiety was not explored before by 
others. The explanation is probably inherent to the rational of the drug design process where only 
one feature is explored at a time. We have found at least two studies performed by Hasegawa et al.
8 
and Oguro et al.
9
 where the importance of the O/S linker atom and the meta/para position relative to 
the urea moiety was analyzed in a series of benzimidazole and pyrrolo[3,2-d]pyrimidine derivatives, 
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respectively. These compounds explore the same VEGFR-2 binding mode with the best clinical 
candidate provided by each study presented as compound A (benzimidazole) and B (pyrrolo[3,2-
d]pyrimidine derivative) (Figure 1). In both studies the O/S-linker was investigated only in para 
position relative to the urea moiety, with the S-linker always providing less potent compounds and 
being discarded for further synthesis. In fact the presence of a S-linker, when compared to similar 
compounds with an O-linker, lowered the VEGFR-2 inhibition potency by 3-fold and 20-fold for the 
benzimidazole and pyrrolo[3,2-d]pyrimidine derivatives, respectively. Similarly, the meta/para 
position relative to the urea was only investigated using an O-linker, with the meta position always 
providing less potent compounds and thus also being discarded for further synthesis. Also 
compounds with the O-linker and urea in the meta position lowered the activity by 6-fold and 55-
fold for the benzimidazole and pyrrolo[3,2-d]pyrimidine derivatives, respectively, when compared to 
compounds with the O-linker in the para position relative to the urea. As far as our knowledge, this 
thieno[3,2-b]pyridine series is the first that presents compounds with a S-linker in the meta position 
relative to the urea moiety with potent inhibition activity against VEGFR-2. This study provides a 
new insight in the field as this substitution pattern was not previously investigated and has been 
thought to be of low potency. 
Typically, for type II VEGFR-2 inhibitors, the terminal aryl ring that occupies the hydrophobic 
pocket is functionalized with hydrophobic substituent groups, the most frequent being methyl 
groups or halogen atoms in meta or para position, although other substitution pattern is observed 
(Figure 1). Based on this information compounds 4d-h were synthetized in an attempt to obtain 
more potent VEGFR-2 inhibitors than compounds 4a-4c. Compounds 4d with a F atom in the para 
position or 4e with a F in the meta position, 4f with a methyl group, 4g with a CF3 both in the meta 
position and 4h with a CF3 in meta and a Cl in the para position, relative to the urea moiety, were 
the most potent VEGFR-2 inhibitors in enzymatic assays with IC50 values of 10, 28, 11, 15 and 16 
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nM, respectively (Table 1). These values are in line with the most potent VEGFR-2 inhibitor agents 
and pending further analysis, but compounds 4d-h can already be considered as potential leads as 
antiangiogenic compounds. This increase of potency in one order of magnitude with hydrophobic 
substituents in the terminal aryl ring provides evidence that the latter in fact occupies the 
hydrophobic pocket in a similar fashion to other known type II inhibitors. 
Although compounds 5 have given high IC50 values it was decided to prepare compounds in this 
series with substituents CF3 and/or Cl present in the Sorafenib, but the IC50 values did not 
significantly decreased (Table 1). 
 
                             Table 1. VEGFR-2 inhibition activity of compounds 3a-c, 4a-h and 5a-e 
Compound 
VEGFR-2; IC50 
a 
(using 10 µM of ATP) 
3a >100000 nM 
3b >100000 nM 
3c >100000 nM 
4a 94 nM  
4b 107 nM 
4c 206 nM 
4d 10 nM 
4e 28 nM 
4f 
4g 
4h 
11 nM 
               15 nM 
                16 nM 
5a 1160 nM 
5b 1390 nM 
5c 
5d 
5e 
8360 nM 
988 nM 
1947 nM 
Staurosporine
b 
6 nM
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(enzymatic
 
kit 
control) 
a
Each IC50 determination is a result of at least four separate determinations. 
b
Staurosporine experimental VEGFR-2 IC50 = 7 nM.
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In order to explain the VEGFR-2 inhibitory activity of compounds 4, we set out to investigate in 
detail the binding mode of compounds 4d and 4f and 5a by performing molecular docking studies. 
 
2.3. Molecular Docking Simulations 
To better understand the structural rational behind the VEGFR-2 inhibition potency observed for the 
synthesized compounds, molecular docking simulations were performed using AutoDock4 software. 
The VEGFR-2 kinase domain crystal structure with PDB code: 3VHE was selected because it 
presented a co-crystallized inhibitor (compound B, Figure 1) with the closest structure compared to 
the compounds prepared in this work. For a suitable comparison, compounds 5a and compounds 4d 
and 4f were docked against the selected structure and then superimposed with the experimental 
structure of compound B (Figure 2A and 2B). The other compounds of series 5 were also docked 
and the obtained docking poses were a near perfect superimposition of compound 5a docking pose.  
So for clearance of representation on figure 2A only compound 5a was used as it is the simplest, 
without substitution in the terminal aryl ring. 
For the less potent compound 5a a similar binding mode pattern to compound B was observed 
(Figure 2A). In both compounds the urea moiety forms two H-bonds with the Glu885 carboxyl 
group, and the C=O urea group forms a third H-bond with the backbone N–H of Asp1046. The 
thieno[3,2-b]pyridine moiety is docked in adenine pocket with a near perfect superimposition to the 
pyrrolo[3,2-d]pyrimidine ring of compound B, and both rings are positioned in order to form the 
critical H-bond with the Cys919 backbone N-H group. The central aryl group is docked on the linker 
region and the terminal aryl ring on the hydrophobic pocket (Figure 2A). However a more detailed 
11 
 
inspection of compound 5a docking pose gives us some insights on why the S-linker in the para 
position is probably less favored compared to the O-linker in the same position. In fact, in order to 
accommodate the network of critical H-bonds and allow a correct pocket occupation of the ring 
systems, the S-linker was stretched to a 109.5
o
 angle when the more stable value for a S-linker angle 
is approximately 90º (Figure 2A). The co-crystallized structure of compound B on the other hand 
presents a O-linker angle of 115.8º that is closer to the ideal 110º angle.
17 
This widening of the S-
linker is energetically unfavorable and probably explain the much lower potency of compound 5a 
(IC50 = 1166 nM) compared to compound B (IC50 = 6.2 nM). It is likely that there may be a protein 
shifting in the active site to relieve this very high energy situation and the docking presented in 
Figure 2A is likely to be an approximation of the actual interaction between compound 5a and the 
active site. 
For the most potent compounds 4d and 4f (IC50 of 10 and 11 nM, respectively) the same 
superimposition with compound B is also presented (figure 2B). A closer inspection of the docked 
poses shows that, due to the presence of the S-linker in the meta position relative to the urea group, 
the central aryl ring is placed deeper inside the linker region, when compared to compound B. The 
S-linker sharper angle (100.4º) is close to the ideal 90º angle and now appears to work in favor of 
increasing VEGFR-2 inhibitory potency by enabling a more favored occupation of the linker region 
by the central aryl ring. In fact this ring is superimposed with the F atom of compound B, further 
evidence that this linker region occupation pattern is possible and probably favored.  
The higher inhibition potency of compound 4d with an F atom in the para position and 4f with a 
methyl group in the meta position, relative to the urea moiety, when compared to compound 4a with 
no substitution, is also widely observed for other known type II inhibitors (Figure 1) and it is due to 
a better occupation of the hydrophobic pocket.
13-15
 This observation further demonstrates that the 
predicted docked poses are probably correct. 
12 
 
 
 
Figure 2. Docking pose superimposition of: (A) compound 5a (green) and (B) compounds 4d and 4f 
(green), with the co-crystallized structure of compound B (cyan).  A partial surface representation of 
the VEGFR-2 kinase binding site is depicted with the relevant residues presented (white). H-bonds 
are represented in dashed red lines (distances between 2.8 and 3.4 Å). Structures were prepared 
using PyMOL.
18
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2.4. Cell Culture Assays 
The best compounds in enzymatic assays (4a-h) against VEGFR-2 tyrosine kinase domain were 
examined in cell culture viability and proliferation assays using HUVECs stimulated by VEGF. Cell 
viability was first analyzed by MTS assay (Figure 3). The effects of compounds 4a-f at 0.1 to 10 µM 
on HUVECs viability are shown in Figure 3A. Cell viability was reduced by each compound at a 
dose-dependent manner, reaching statistical significance at the concentration of 5.0 µM or higher. 
The effects of compounds 4g and 4h on HUVECs viability were analyzed. Given the similarity of 
the hydrophobic chemical pattern substitution of Sorafenib, this drug was used as a positive control 
for compounds 4g and 4h, these two compounds being used at 1.0 to 10 µM, the concentrations 
established for Sorafenib in cell culture assays (Figure 3B). Compound 4g significantly reduced the 
cell viability at 10 µM, while compound 4h did it at 2.5, 5.0 and 10 µM. Nevertheless, they only 
affected more than 50% cell viability (4g = 44%, 4h = 26%), revealing a cytotoxic effect on 
HUVECs for the highest concentration tested (10 µM), as Sorafenib (18%). Altogether, these 
findings reveal that every compound was able to decrease HUVECs viability. Though, compounds 
4g and 4h presented significant reductions at lower concentrations. 
 
14 
 
 
Figure 3. Evaluation of the HUVECs viability effects of compounds 4a-h and Sorafenib on VEGF-
stimulated HUVECs by MTS assay. (A) HUVECs viability upon treatment with compounds 4a-f at 
concentrations of 0.1 to 10 µM. (B) HUVECs viability upon treatment with compounds 4g, 4h and 
Sorafenib at 1.0 to 10 µM. Results were obtained after 24 h, and are expressed as percentage of 
control (0.1% DMSO with 60 ng/mL VEGF) as means ± SEM of at least three independent 
experiments, performed in triplicate. 
*
 p < 0.05 versus control.  
 
A proliferation assay was then assessed using the BrdU incorporation, a thymidine analogue which 
incorporates into DNA of dividing cells (Figure 4). Compounds 4a (R
1 
= H), 4c (R
1 
= CN), and 4f 
(R
2 
= Me) showed a statistical significant antiproliferative effect at 1.0 µM (Figure 4A) without 
significantly affecting cell viability (Figure 3A). Remarkably, compounds 4b (R
1 
= OMe), 4d (R
1 
= 
F) and 4e (R
2
 = F) showed a higher antiproliferative effect, revealing a statistical significant cell 
proliferation decrease at 0.5 µM (Figure 4A) without affecting cell viability (Figure 3A). 
Compounds 4g (R
2 
= CF3), 4h (R
1 
= Cl; R
2 
= CF3) significantly inhibited proliferation of HUVECs 
15 
 
at 2.5 and 5.0 µM, without high cytotoxic effect. Sorafenib is known to prevent cell growth in 
endothelial cells.
7
 Interestingly enough, compounds 4g and 4h exhibit, thus, a more noteworthy 
effect than Sorafenib, which only significantly affected proliferation of these cells at 5.0 M (Figure 
4B). 
These results showed that all the tested compounds considerably inhibit VEGF-stimulated HUVECs 
proliferation in a dose-dependent manner at low concentrations. 
 
  
Figure 4. Effect of compounds 4a-4h and Sorafenib on VEGF-induced HUVECs proliferation 
assessed by BrdU incorporation assay. (A) HUVECs proliferation upon treatment with compounds 
4a-4f at concentrations of 0.1 to 10 µM.  (B) HUVECs proliferation upon treatment with compounds 
4g, 4h and Sorafenib at concentrations of 1.0 to 10 µM. Results were obtained after 24 h incubation, 
and are expressed as percentage of control (0.1% DMSO with 60ng/mL VEGF) as means ± SEM of 
at least three independent experiments, performed in triplicate. 
*
 p < 0.05 versus control.  
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2.5. Effect on Apoptosis 
The induction of apoptosis is a therapeutic approach for cancer treatment. Several anticancer drugs, 
including some VEGFR-2 inhibitors can promote apoptosis.
19
 The effect of compounds 4a-h on cell 
apoptosis was then evaluated by TUNEL assay (Figure 5). Concentrations of 0.1 to 1.0 µM of 
compounds 4a-4f were used in the subsequent assays due to their antiproliferative effect without 
cytotoxic effect at these concentrations (Figure 5A). An increase in apoptosis was observed when 
HUVECs were incubated with increasing concentrations of the tested compounds for 24 h, reaching 
statistical significance only for 4b-4d at the highest concentration tested (1.0 µM) in comparison to 
control. These findings indicate that besides the effects of these three compounds in HUVECs 
proliferation, they also induce apoptosis. Compounds 4a, 4e and 4f increased apoptosis in a dose-
dependent manner, but not with statistical significance (Figure 5A). 
For compounds 4g and 4h, the concentrations selected for this and the following assays were 2.5 and 
5.0 µM since they are the lowest concentrations of these compounds that have shown an 
antiproliferative effect without being cytotoxic to HUVECs (Figure 3B and 4B). As shown in Figure 
5B, 4g and 4h significantly increase apoptosis at 5.0 µM. Many studies report that Sorafenib induces 
apoptosis.
19 
The findings in this study reveal that compounds 4g and 4h exhibited a higher effect 
than Sorafenib in apoptosis.
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Figure 5. Effect of compounds 4a-4h and Sorafenib on apoptosis assessed by TUNEL assay. (A) 
HUVEC apoptosis upon treatment with compounds 4a-4f at concentrations of 0.1 to 1.0 µM.  (B) 
HUVEC apoptosis upon treatment with compounds 4g, 4h and Sorafenib at concentrations of 2.5 
and 5.0 µM. Bars represent the percentage of apoptotic cells evaluated by ratio between TUNEL-
stained cells and DAPI-stained nuclei in every culture. Results were obtained after 24 h, and are 
expressed as mean ± SEM of at least three independent experiments. 
*
 p < 0.05 versus control.  
 
2.6. Effect on HUVECs migration  
Cell migration is an essential feature for endothelial cells in angiogenesis.
20
 Therefore, we next 
examined the effect on the HUVECs chemotactic motility of the most promising compounds 4d-4h, 
according to the previous results on HUVECs viability and proliferation, by wound-healing assay 
(Figure 6). The results show that compounds 4d-4f significantly inhibited VEGF-induced HUVECs 
18 
 
migration in a dose-dependent manner ranging from 0.1 µM to 5.0 µM (Figure 6A). Treatment with 
compounds 4g and 4h significantly inhibited HUVECs migration at concentrations of 2.5 µM and 
5.0 µM showing a similar effect to Sorafenib (Figure 6B). These findings regarding Sorafenib effect 
in endothelial cell migration were corroborated by previous studies in the literature.
21
 Nonetheless, 
incubation with compound 4h was more effective than Sorafenib, implying a better inhibitory role in 
this relevant angiogenic step. 
 
  
 
Figure 6. Effect of compounds 4d-4h on HUVECs migration (wound-healing assay) after 
incubation during 24 h. Representative fields were photographed, 100  magnification. The graphics 
shows the quantitative effect of compounds 4d-4f (A), 4g-4h and Sorafenib (B) on VEGF-induced 
19 
 
HUVECs motility. Data presented the percentage of control, as mean ± SEM of three independent 
experiments. 
*
 p < 0.001 versus control.  
 
2.7. Effect on HUVECs tube formation 
To elucidate the possible mechanisms of angiogenesis inhibition, tube formation ability of 
endothelial cells, which is also a critical step in the angiogenic process, was assessed in HUVECs. 
As shown in Figure 7, HUVECs plated on a Matrigel coated plate formed capillary-like structures in 
cells cultured in the absence of compounds (control). A significant decrease of these structures was 
observed whenever cells were incubated with compounds 4d-4f at concentrations of 0.5 to 5.0 µM, 
in a dose-dependent manner (Figure 7A). In the presence of compounds 4g, 4h or Sorafenib at 
concentrations of 2.5 and 5 µM, tube formation of HUVECs was significantly reduced (Figure 7B), 
except for 4g at 2.5 µM. This assay is a hallmark of angiogenesis evaluation in vitro. Interestingly, 
prevention of this process was also accomplished by every compound tested in the present study in a 
significant manner, implying thus, the important antiangiogenic role of these molecules. 
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Figure 7. Effect of compounds 4d-4h on VEGF-induced capillary-like tube formation of HUVEC 
through Matrigel in 24 h. Representative fields were photographed, 100  magnification. Bars show 
the quantitative effect of compounds 4d-4f (A), 4g-4h and Sorafenib (B) on VEGF-induced HUVEC 
tube formation. Data were presented as the percentage of control, as mean ± SEM of three 
independent experiments. 
*
 p < 0.001 versus control. 
 
2.8. Effect on VEGFR-2 phosphorylation  
The results presented herein were obtained in VEGF stimulated HUVECs cultures, implying that the 
compounds analyzed were able to exert their effects by interfering with VEGF signalling pathway. 
To confirm this hypothesis, a Western blotting assay for total and phosphorylated (active) VEGFR-2 
was performed. At 1.0 µM compounds 4a, 4b and 4d-4f significantly decreased the active form of 
VEGFR-2 (Figure 8A-D) (*p<0.05 vs. control). Moreover, compounds 4g and 4h, at concentrations 
of 2.5 and 5.0 µM, significantly decreased VEGFR-2 phosphorylation, presenting a better effect than 
Sorafenib (Figure 8E and F).  
VEGF signalling pathway through the VEGFR-2 tyrosine kinase phosphorylation displays a crucial 
role in angiogenesis, namely, enhancing endothelial cell survival, proliferation and migration.
22 
Many other signalling pathways are involved in angiogenesis, nevertheless, VEGF signalling, an 
angiogenic surrogate pathway, which is involved in the whole multistep process, from cell 
proliferation, migration, invasiveness capacity, anastomosis, ending up in the assembly of newly 
formed vascular structures. Therefore, we believe that inhibiting this pathway is an effective 
approach against angiogenesis.  
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Figure 8: (A, C and E) Evaluation of phosphorylated and total VEGFR-2 expression in HUVECs 
after incubation with compounds 4a-4h, by Western blotting. Representative bands obtained after 
immunostaining are shown. (B, D and F) Quantification by densitometry and mean relative intensity 
by comparison of the relative intensity of activated VEGFR-2 after normalization with total 
VEGFR-2 intensity. Data presented as mean ± SEM of two independent experiments. 
*
 p < 0.05 
versus control.  
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3. Conclusion 
In conclusion the synthesis of new 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 
3, 4 and 5 in overall good yields is reported. Compounds 4, with the arylurea in the meta position 
relative to the S-linker, showed to be the most potent phosphorylation tyrosine kinase VEGFR-2 
inhibitors, presenting IC50 values between 10-206 µM in enzymatic assays, depending on the 
substituents on the terminal phenyl ring. To better understand these results, molecular docking 
simulations were performed. The predicted docked poses were analyzed in detail and a plausible 
explanation for compounds 4 and in particularly for 4d and 4f potency (10 and 11 nM) was obtained 
based on the simultaneous presence of a S-linker and the arylurea moiety in the meta position as a 
new substitution pattern for the type II VEGFR-2 inhibitors. The importance of hydrofobic 
substituents in 4d and 4f (F and Me, respectively) in the terminal phenyl ring is also highlighted. 
These chemical features place the thieno[3,2-b]pyridine and the terminal aryl ring in close 
superimposition to a pyrrolo[3,2-d]pyrimidine derivative, type II co-crystallized VEGFR-2 ligand. 
Compounds 4g an 4h with pattern substitution closer to Sorafenib showed also low IC50 values (15 
and 16 nM).  
Our results showed that compounds 4 affect various steps of angiogenesis including endothelial cell 
proliferation, apoptosis, migration and capillary structure formation in a dose dependent manner. 
In the present study we found that compounds 4 significantly block the tyrosine kinase 
phosphorylation of VEGFR-2, as observed by Western blotting in vitro, suggesting these compounds 
as potent VEGFR-2 inhibitors.  
As far as our knowledge the S-linker in the meta position relative to the urea moiety constitutes a 
new substitution pattern that has not been disclosed in other known type II VEGFR-2 inhibitors.  
This can thus be regarded as an interesting feature for the synthesis of new compounds with higher 
VEGFR-2 inhibitory activity and also for other scaffolds exploring the same VEGFR-2 binding 
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conformation. 
Although future studies, namely using animal models, are crucial, overall, our findings support the 
hypothesis that all these molecules are potent antiangiogenic agents.  
 
4. Experimental Section 
 
4.1. Synthesis 
Melting points (
o
C) were determined in a Stuart SMP3 and are uncorrected. 
1
H and 
13
C NMR 
spectra were recorded on a Varian Unity Plus at 300 and 75.4 MHz, respectively or on a Bruker 
Avance III at 400 and 100.6 MHz, respectively, and the chemical shifts were quoted in parts per 
million (ppm) referenced to the appropriate non-deuterated solvent peak relative to 0.0 ppm for 
tetramethylsilane. Two dimensional 
1
H-
13
C correlations were performed to attribute some signals. 
Mass spectra (MS) EI -TOF or ESI-TOF and HRMS on the M
+
 or on the [M+H]
+
 were performed by 
the mass spectrometry service of the University of Vigo, C.A.C.T.I., Spain and the low resolution 
MS ESI of compounds 4g, 4h, 5d and 5e were performed by direct injection on a ThermoFinigan 
spectrophotometer LC-MS. Elemental Analysis was performed on a LECO CHNS 932 Elemental 
Analyser. The compounds yielded data consistent with a purity of at least 95% as compared with the 
theoretical values. The reactions were monitored by thin layer chromatography (TLC) using 
Macherey-Nagel pre-coated aluminium silica gel 60 sheets (0.20 mm) with UV254 indicator. 
Column chromatography was performed on Panreac, Silica Gel 60, 230-400 mesh. Ether refers to 
diethylether. Petroleum ether refers to the boiling range 40-60 
o
C. Aminothiophenols were purchased 
from Sigma-Aldrich with purity ≥ 96%. 
 
4.1.1. General synthesis procedure for compounds 2a-c: In a flask with DMF (5 mL), compound 1, 
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the aminothiophenol (1equiv.) and K2CO3 (4equiv.) were heated at 140 ºC for 2h. After cooling 
water (5 mL) and ethyl acetate (5 mL) were added. The phases were separated and the aqueous 
phase was extracted with more ethyl acetate (2x5mL). The organic phase was dried (MgSO4) and 
filtered. The solvent was evaporated under reduced pressure giving an oil which was submitted to 
column chromatography. 
4.1.1.1. 2-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2a): Compound 1 (150 mg, 0.880 mmol) and  2-
aminothiophenol (110 mg) and the general procedure was followed. Column chromatography using 
70% ether/petroleum ether gave compound 2a as an oil (180 mg, 80%). 
1
H NMR (DMSO-d6, 300 
MHz): δ 5.54 (br s, 2H, NH2), 6.57 (d, J = 5.2 Hz, 1H, 6’-H), 6.62-6.67 (m, 1H, 4-H), 6.87 (dd, J = 
8.4 and 1.5 Hz, 1H, 6-H), 7.25-7.30 (m, 1H, 5-H), 7.37 (dd, J = 8.4 and 1.5 Hz, 1H, 3-H), 7.57 (d, J 
= 5.6 Hz, 1H, HetArH), 8.14 (d, J = 5.6 Hz, 1H, HetArH), 8.42 (d, J = 5.2 Hz, 1H, 5’-H) ppm.13C 
NMR (DMSO-d6, 75.4 MHz,): δ 107.2 (C), 114.0 (6’-CH), 115.3 (6-CH), 116.9 (4-CH), 124.9 (CH), 
129.3 (C), 131.6 (CH), 132.3 (5-CH), 137.4 (3-CH), 142.5 (C), 147.2 (5’-CH), 151.1 (C), 155.7 (C) 
ppm. MS (EI- TOF) m/z (%): 258.03 (M
+
, 100). HRMS (EI-TOF): calcd for C13H10N2S2 [M
+
] 
258.0285, found 258.0284. 
4.1.1.2. 3-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2b): Compound 1  (200 mg, 1.20 mmol) and  3-
aminothiophenol (125 mg) and the general procedure was followed. Column chromatography using 
45% ether/petroleum ether gave compound 2b as a yellow solid (280 mg, 90%). Mp 106-107 ºC. 
1
H 
NMR (DMSO-d6, 400 MHz): δ 5.40 (br s, 2H, NH2), 6.69-6.71 (m, 2H, 4 and 6-H), 6.75-6.76 (m, 
1H, 2-H), 6.87 (d, J = 4.8 Hz, 1H, 6’-H), 7.14 (apparent t, J = 8 Hz, 1H, 5-H), 7.58 (d, J = 5.6 Hz, 
1H, HetArH), 8.14 (d, J = 5.6 Hz, 1H, HetArH), 8.49 (d, J = 4.8 Hz, 1H, 5’-H) ppm. 13C MNR 
(DMSO-d6, 100.6 MHz): δ 115.2 (CH), 116.0 (6’-CH), 118.7 (2-CH), 121.0 (CH), 125.0 (CH), 
128.1 (C), 130.3 (C), 130.5 (5-CH), 131.8 (CH), 142.8 (C), 147.4 (5’-CH), 150.3 (C), 155.7 (C) 
ppm.  MS (ESI- TOF) m/z (%): 259.03 (M
+
+H, 100). HRMS (ESI-TOF): calcd for C13H11N2S2 
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[M
+
+H] 259.0358, found 259.0358. Anal. Cald. for C13H10N2S2: C 60.43, H 3.90, N 10.84, S 24.82 
%; found 60.57, H 4.01, N 11.02, S 24.42%. 
4.1.1.3. 4-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2c): Compound 1 (150mg, 0.880mmol) and  4-
aminothiophenol (110 mg) was treated according to the general procedure. Column chromatography 
using 40% ether/petroleum ether gave compound 2c as a yellow solid (210 mg, 90%). Mp 215-216 
ºC. 
1
H NMR (CDCl3, 400 MHz): δ 3.85 (br s, 2H, NH2), 6.70 (d, J = 5.2 Hz, 1H, 6’-H), 6.76 (d, J = 
8.4 Hz, 2H, 2 and 6-H), 7.40 (d, J = 8.4 Hz, 2H, 3 and 5-H), 7.64 (d, J = 5.6 Hz, 1H, HetArH), 7.78 
(d, J = 5.6 Hz, 1H, HetArH), 8.39 (d, J = 5.2 Hz, 1H, 5’-H) ppm. 13C NMR (CDCl3,100.6 MHz): δ 
114.5 (6 ‘-CH), 116.0 (2 and 6-CH), 124.2 (CH), 130.2 (C), 131.1 (CH), 135.8 (C), 136.4 (C), 137.4 
(3 and 5-CH), 145.2 (5’-CH), 148.7 (C), 153.6 (C) ppm. MS (EI- TOF) m/z (%): 258.03 (M+, 100). 
HRMS (EI-TOF): calcd for C13H10N2S2 [M
+
] 258.0285, found 258.0289.  Anal. Cald. for 
C13H10N2S2: C 60.43, H 3.90, N 10.84, S 24.82 %; found 60.59, H 4.11, N 10.90, S 24.40%. 
4.1.2. General procedure for the synthesis of 1,3-diarylureas 3-5: Compounds 2a-c and different 
arylisocyanates (1equiv.) in 6 mL CH2Cl2: THF (1:1) were left stirring at room temperature for 12 h. 
If a precipitate does not come out after this time, hexane (3-5 mL) was added to the mixture to 
precipitate the product. This was filtered under vacuum to give the corresponding 1,3-diarylureas. 
4.1.2.1. 1-Phenyl-3-[2-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (3a): From compound 2a (100 
mg, 0.390 mmol) and phenylisocyanate (50.0 mg) compound 3a was isolated as a green solid (95.0 
mg, 65%). Mp 198-199 ºC. 
1
H NMR (DMSO-d6, 300MHz): δ 6.56 (d, 1H, J = 4.8 Hz), 6.92-6.98 
(m, 1H), 7.12-7.18 (m, 1H), 7.24-7.29 (m, 2H), 7.37-7.46 (m, 2H), 7.54-7.63 (m, 3H), 8.18 (d, 1H, J 
= 5.6 Hz), 8.28-8.31 (m, 1H), 8.45 (d, 1H,  J = 4.8 Hz), 8.49 (br s, 1H, NH), 9.36 (br s, 1H, NH) 
ppm. 
13
C NMR (DMSO-d6, 75.4MHz): δ 114.3 (CH), 115.3 (C), 118.2 (CH), 118.3 (2×CH), 121.3 
(CH), 122.1 (CH), 123.6 (CH), 125.0 (CH), 128.8 (2×CH), 129.5 (C), 131.9 (CH), 137.3 (CH), 
139.3 (C), 142.3 (C), 142.4 (C), 147.5 (CH), 152.2 (C), 155.8 (C) ppm. MS (ESI- TOF) m/z (%): 
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378.07 (M
+
+H, 100) HRMS (ESI-TOF): calcd for C20H16N3OS2 [M
+
+H] 378.0729, found 378.0723. 
Anal. Cald. for C20H15N3OS2: C 63.64, H 4.01, N 11.13, S 16.99%; found C 63.83, H 4.13, N 10.83, 
S 16.60%.  
4.1.2.2. 1-(4-Methoxyphenyl)-3-[2-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (3b): From 
compound 2a (100 mg, 0.390 mmol) and 4-methoxyphenylisocyanate (83.0 mg), compound 3b was 
isolated as a green solid (100 mg, 63%). Mp 198-199 ºC. 
1
H NMR (DMSO-d6, 400 MHz): δ 3.68 (s, 
3H, OMe), 6.55 (d, J = 5.2 Hz, 1H), 6.82 (d, J = 9.2 Hz, 2H), 7.13 (m, 1H), 7.28 (d, J = 9.2 Hz, 2H), 
7.53-7.61 (m, 3H), 8.18 (d, J = 5.6 Hz, 1H), 8.31 (dd, J = 8.4 and 1.2 Hz, 1H), 8.38 (br s, 1H, NH), 
8.45 (d, J = 5.2 Hz, 1H), 9.17 (br s, 1H, NH) ppm. 
13
C NMR (DMSO-d6,100.6 MHz): δ 55.1 (OMe), 
114.0 (2xCH), 114.2 (CH), 114.9 (C), 120.1 (2xCH), 121.0 (CH), 123.3 (CH), 125.0 (CH), 129.4 
(C), 131.8 (CH), 131.9 (CH), 132.2 (C), 137.2 (CH), 142.3 (C), 142.5 (C), 147.5 (CH), 152.3 (C), 
154.6 (C), 155.8 (C) ppm. MS (ESI- TOF) m/z (%): 408.08 (M
+
+H, 100). HRMS (ESI-TOF): calcd 
for C21H18N3O2S2 [M
+
+H] 408.0835, found 408.0832. Anal. Cald. for C21H17N3O2S2: C 61.89, H 
4.20, N 10.31, S 15.74%; found C 62.01, H 4.05, N 11.00, S 15.33%. 
4.1.2.3. 1-(4-Cyanophenyl)-3-[2-(thieno[3,2-b]piridin-7-ylthio)phenyl]urea (3c): From compound 
2a (60.0 mg, 0.230 mmol) and 4-cyanophenylisocyanate (37.0 mg) compound 3c was isolated as a 
green solid (60.0 mg, 65%). Mp 208-209 ºC. 
1
H NMR (DMSO-d6, 300 MHz): δ 6.57 (d, J = 5.2 Hz, 
1H), 7.17-7.22 (m, 1H), 7.58-7.60 (m, 5H), 7.68 (d, J = 9.2 Hz, 2H), 8.17 (d, J = 5.6 Hz, 1H), 8.24 
(dd, J = 8.4 and 1.5 Hz, 1H), 8.45 (d, J = 5.2 Hz, 1H), 8.65 (br s, 1H, NH), 9.80 (br s, 1H, NH) ppm. 
13
C NMR (DMSO-d6, 75.4 MHz): δ 103.6 (C), 114.5 (CH), 116.3 (C), 118.1 (2xCH), 119.2 (C), 
121.7 (CH), 124.3 (CH), 125.0 (CH), 129.6 (C), 131.9 (CH), 131.9 (CH), 133.3 (2xCH), 137.2 
(CH), 141.7 (C), 142.1 (C), 143.8 (C), 147.5 (CH), 151.9 (C), 155.8 (C) ppm. MS (ESI- TOF) m/z 
(%): 403.07 (M
+
+H, 100). HRMS (ESI-TOF): calcd for C21H15N4OS2 [M
+
+H] 403.0682, found 
403.0689. Anal. Cald. for C21H14N4OS2: C 62.67, H 3.51, N 13.92, S 15.93%; found C 62.95, H 
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3.32, N 14.12, S 15.51%. 
4.1.2.4. 1-Phenyl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (4a): From compound 2b (80.0 
mg, 0.300 mmol) and phenylisocyanate (36.0mg) compound 4a was isolated as a yellow solid 
(70mg, 63%). Mp 94-95 ºC. 
1
H NMR (DMSO-d6, 400 MHz): δ 6.95 (d, J = 5.2 Hz, 1H), 6.96-6.98 
(m, 1H), 7.17-7.20 (m, 1H), 7.24-7.28 (m, 2H), 7.39-7.44 (m, 3H), 7.49-7.52 (m, 1H), 7.60 (d, J = 
5.6 Hz, 1H), 7.78-7.79 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.70 (br s, 1H, 
NH), 8.90 (br s, 1H, NH) ppm. 
13
C NMR (DMSO-d6, 100.6 MHz): δ 116.5 (CH), 118.4 (2xCH), 
119.3 (CH), 122.1 (CH), 122.8 (CH), 125.0 (CH), 127.0 (CH), 128.7 (2xCH), 128.8 (C), 130.5 
(CH), 130.8 (C), 132.0 (CH), 139.4 (C), 141.2 (C), 141.9 (C), 147.6 (CH), 152.4 (C), 155.9 (C) 
ppm. MS (ESI- TOF) m/z (%): 378.07 (M
+
+H, 100) HRMS (ESI-TOF): calcd for C20H16N3OS2 
[M
+
+H] 378.0729, found 378.0728. Anal. Cald. for C20H15N3OS2: C 63.64, H 4.01, N 11.13, S 
16.99%; found C 63.86, H 3.80, N 11.33, S 16.59%. 
4.1.2.5. 1-(4-Methoxyphenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (4b): From 
compound 2b (100 mg, 0.390 mmol) and 4-methoxyphenylisocyanate (58.0 mg), compound 4b was 
isolated as a yellow solid (100 mg, 64%). Mp 132-133 ºC. 
1
H NMR (DMSO-d6, 400 MHz): δ 3.69 
(s, 3H, OMe), 6.84 (d, J = 8.8 Hz, 2H), 6.92 (d,  J = 4.8 Hz, 1H), 7.16-7.18 (m, 1H), 7.31 (d,  J = 8.8 
Hz, 2H), 7.30-7.33 (m, 1H), 7.48-7.51 (m, 1H), 7.60 (d, J = 5.6 Hz, 1H), 7.77-7.78 (m, 1H), 8.16 (d, 
J = 5.6 Hz, 1H), 8.50 (br s, 1H, NH), 8.52 (d, J = 4.8 Hz, 1H), 8.80 (br s, 1H, NH) ppm. 
13
C NMR 
(DMSO-d6, 100.6 MHz): δ 55.1 (OMe), 113.9 (2xCH), 116.5 (CH), 119.2 (CH), 120.3 (2xCH), 
122.7 (CH), 125.0 (CH), 126.9 (CH), 128.8 (C), 130.4 (CH), 130.7 (C), 132.0 (CH), 132.3 (C), 
141.4 (C), 141.9 (C), 147.6 (CH), 152.6 (C), 154.6 (C), 155.9 (C) ppm. MS (ESI- TOF) m/z (%): 
408.08 (M
+
+H, 100). HRMS (ESI-TOF): calcd for C21H18N3O2S2 [M
+
+H] 408.0835, found 
408.0833. Anal. Cald. for C21H17N3O2S2: C 61.89, H 4.20, N 10.31, S 15.74%; found C 62.20, H 
4.45, N 10.02, S 15.35%. 
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4.1.2.6. 1-(4-Cyanophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (4c): From compound 
2b (60.0 mg, 0.230 mmol) and 4-cyanophenylisocyanate (35.0 mg), compound 4c was isolated as a 
yellow solid (65.0 mg, 65%). Mp 168-169 ºC. 
1
H NMR (DMSO-d6, 400  MHz): δ 6.95 (d,  J = 5.2 
Hz, 1H), 7.21-7.24 (m, 1H), 7.42-7.46 (m, 1H), 7.52-7.55 (m, 1H), 7.59 (d, J = 5.6 Hz, 1H), 7.60 (d, 
J = 8.8 Hz, 2H), 7.71 (d, J = 8.8 Hz, 2H), 7.76-7.77 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.53 (d,  J = 
5.2 Hz, 1H), 9.07 (br s, 1H, NH), 9.23 (br s, 1H, NH) ppm. 
13
C NMR (DMSO-d6, 100.6 MHz): δ 
103.5 (C), 116.7 (CH), 118.2 (2xCH), 119.2 (C), 119.6 (CH), 123.0 (CH), 125.0 (CH), 127.5 (CH), 
129.0 (C), 130.5 (CH), 130.9 (C), 132.0 (CH), 133.2 (2xCH), 140.7 (C), 141.6 (C), 143.9 (C), 147.6 
(CH), 152.0 (C), 155.9 (C) ppm. MS (ESI- TOF) m/z (%): 403.07 (M
+
+H, 100) HRMS (ESI-TOF): 
calcd for C21H15N4OS2 [M
+
+H] 403.0682, found 403.0680. Anal. Cald. for C21H14N4OS2: C 62.67, 
H 3.51, N 13.92, S 15.93%; found C 62.37, H 3.80, N 14.13, S 15.52%. 
4.1.2.7. 1-(4-Fluorophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio]phenyl)urea (4d): From compound 
2b (60.0 mg, 0.230 mmol) and 4-fluorophenylisocyanate (35.0 mg), compound 4d was isolated as a 
white solid (65.0 mg, 71%). Mp 140-141 ºC. 
1
H NMR (DMSO-d6, 400 MHz): δ 6.93 (1H, d, J = 5.2 
Hz), 7.07-7.12 (m, 2H), 7.18-7.20 (m, 1H), 7.39-7.44 (m, 3H), 7.50-7.52 (m, 1H), 7.60 (d, J= 5.6 
Hz, 1H), 7.76-7.77 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.52 (d, J = 5.2Hz, 1H), 8.73 (br s, 1H, NH), 
8.89 (br s, 1H, NH) ppm. 
13
C NMR (DMSO-d6, 100.6 MHz): δ 115.3 (d, J = 22 Hz, 2×CH), 116.6 
(CH), 119.4 (CH), 120.2 (d, J = 7.0 Hz, 2×CH), 122.8 (CH), 125.1 (CH), 127.1 (CH), 128.9 (C), 
130.5 (CH), 130.8 (C), 132.0 (CH), 135.7 (C), 141.2 (C), 141.9 (C), 147.6 (CH), 152.5 (C), 155.9 
(C), 157.5 (d, J = 238 Hz, CF) ppm. MS (ESI- TOF) m/z (%): 396.06 (M
+
+H, 100). HRMS (ESI-
TOF): calcd for C20H15FN3OS2 [M
+
+H] 396.0635, found 396.0634. Anal. Cald. for C20H14FN3OS2: 
C 60.74, H 3.57, N 10.63, S 16.22%; found C 61.01, H 3.28, N 10.35, S 15.81%. 
4.1.2.8. 1-(3-Fluorophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (4e): From compound 
2b (60.0 mg, 0.230 mmol) and 3-fluorophenylisocyanate (35.0 mg) compound 4e was isolated as a 
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white solid (63.0 mg, 69%). Mp 104-105 ºC. 
1
H NMR (DMSO-d6, 400 MHz,): δ 6.77-6.78 (m, 1H), 
6.93 (d, 1H, J = 5.2 Hz), 7.09-7.11 (m, 2H), 7.19-7.20 (m, 1H), 7.21-7.29 (m, 1H), 7.41-7.52 (m, 
2H), 7.53-7.54 (m, 1H), 7.60 (d, 1H, J = 5.6 Hz), 7.7-7.7 (m, 1H,), 8.16 (d, 1H, J = 5.6 Hz), 8.52 (d, 
1H, J = 5.2 Hz), 8.94 (br s, 1H, NH), 8.96 (br s, 1H, NH) ppm. 
13
C NMR (DMSO-d6, 100.6 MHz): δ 
105.0 (d, J = 26 Hz, CH), 108.4 (d, J = 21 Hz, CH), 114.1 (d, J = 2 Hz, CH), 116.6 (CH), 119.5 
(CH), 122.9 (CH), 125.0 (CH), 127.3 (CH), 128.9 (C), 130.3 (d, J = 9.6 Hz, CH), 130.5 (CH), 130.8 
(C), 132.0 (CH), 140.9 (C), 141.3 (d, J = 11.5 Hz, C), 141.8 (C), 147.6 (CH), 152.2 (C), 155.9 (C), 
162.3 (d, J = 240 Hz, CF) ppm. MS (ESI- TOF) m/z (%): 396.06 (M
+
+H, 100). HRMS (ESI-TOF): 
calcd for C20H15FN3OS2 [M
+
+H] 396.0635, found 396.0627. Anal. Cald. for C20H14FN3OS2: C 
60.74, H 3.57, N 10.63, S 16.22%; found C 61.03, H 3.33, N 10.30, S 15.82%. 
4.1.2.9. 1-[3-(Thieno[3,2-b]pyridin-7-ylthio)phenyl]-3-m-tolylurea (4f): From compound 2b (60.0 
mg, 0.230 mmol) and m-tolylisocyanate (35.0 mg) compound 4f was isolated as a white solid (65.0 
mg, 72%). Mp 157-158 ºC. 
1
H NMR (DMSO-d6, 400 MHz): δ 2.25 (s, 3H, CH3), 6.77-6.79 (m, 1H), 
6.93 (d, 1H, J = 4.8 Hz), 7.11-7.20 (m, 3H), 7.26-7.29 (m, 1H), 7.39-7.44 (m, 1H), 7.49-7.51 (m, 
1H), 7.60 (d, 1H, J = 5.6 Hz), 7.79-7.80 (m, 1H), 8.16 (d, 1H, J = 5.6 Hz), 8.52 (d, 1H, J = 4.8Hz), 
8.61 (br s, 1H, NH), 8.87 (br s 1H, NH) ppm. 
13
C NMR (DMSO-d6, 100.6 MHz): δ 21.2 (CH3), 
115.5 (CH), 116.5 (CH), 118.9 (CH), 119.3 (CH), 122.8 (CH), 122.8 (CH), 125.0 (CH), 127.0 (CH), 
128.6 (CH), 128.8 (C), 130.5 (CH), 132.0 (CH), 137.9 (C), 139.3 (C), 139.6 (C), 141.2 (C), 141.9 
(C), 147.6 (CH), 152.3 (C), 155.9 (C) ppm. MS (ESI- TOF) m/z (%): 392.09 (M
+
+H, 100). HRMS 
(ESI-TOF): calcd for C21H18N3OS2 [M
+
+H] 392.0886, found 392.0894. Anal. Cald. for 
C21H17N3OS2: C 64.42, H 4.38, N 10.73, S 16.38%; found C 64.24, H 4.26, N 11.03, S 15.97%. 
4.1.2.10. 1-[3-(Trifluoromethyl)phenyl]-3-[3-(thieno[3,2b]pyridin-7-ylthio)phenyl]urea (4g): From 
3-(thieno[3,2-b]pyridine-7-ylthio)aniline (100 mg, 0.387 mmol) and 3-
(trifluoromethyl)phenylisocyanate (72.4 mg, 53.4 µL, 0.387 mmol ) compound 4g was isolated as a 
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beige solid (86.0 mg, 50%) Mp 138-140ºC. 
1
H NMR (DMSO-d6, 400 MHz): 6.93 (d, J = 4.8 Hz, 
6’’’-H), 7.23 (br d, 1H), 7.30 (br d, 1H), 7.42-7.57 (m, 4H), 7.60 (d, J = 5.6 Hz, 1H), 7.80 (br s, 1H,), 
7.96 (br s, 1H,), 8.16 (d, J = 5.6 Hz, 1H), 8.53 (d, J = 4.8 Hz, 5’’’-H), 9.03 (s, NH), 9.09 (s, NH). 13C 
NMR (DMSO-d6, 100.6 MHz): 114.30 (q, J = 3.9 Hz, 2’-CH), 116.53 (6’’’-CH), 118.30 (q, J = 3.9 
Hz, 4’-CH), 119.66 (CH), 122.00 (CH), 123.10 (CH), 123.8 (q, J = 273.0 Hz, CF3), 125.0 (CH), 
127.4 (CH), 128.86 (C), 129.5 (q, J = 31 Hz, CCF3), 130.0 (CH), 130.5 (CH), 130.78 (C), 132.1 
(CH), 140.30 (C), 140.90 (C), 142.00 (C), 147.50 (5’’’-CH), 152.39 (C), 155.79 (C) ppm. MS (ESI): 
446.25 (M
+
+H, 100). Anal. Cald. for C21H14F3N3OS2: C 56.62, H 3.17, N 9.43, S 14.40%; found C 
56.31, H 3.28, N 9.70, S 14.80%. 
4.1.2.11. 1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea 
(4h): From 3-(thieno[3,2-b]pyridine-7-ylthio)aniline (78.6 mg, 0.304 mmol) and 4-chloro-3-
(trifluoromethyl)isocyanate (67.4 mg, 0.304 mmol) compound 4h was isolated as a beige solid (87.6 
mg, 60%). Mp 196-198ºC. 
1
H NMR (DMSO-d6, 400 MHz): 6.93 (d, J = 4.8 Hz, 6’’’-H), 7.23 (br d, 
1H), 7.43 (apparent t, J = 8.0 Hz, 4’’-H), 7.54-7.64 (4H, m), 7.77 (apparent t, J = 2.0 Hz, 2’’-H), 
8.06 (d, J = 2.4 Hz, 2’-H), 8.16 (d, J = 5.2 Hz, 1H), 8.52 (d, J = 4.8 Hz, 5’’’-H), 9.07 (s, NH), 9.20 
(s, NH). 
13
C NMR (DMSO-d6, 100.6 MHz): 116.6 (6’’’-CH), 116.9 (q, J = 6.0 Hz, 2’-CH), 119.7 
(CH), 122.5 (C), 122.8 (q, J = 272.6 Hz, CF3), 123.2 (CH), 123.3 (CH), 125.0 (CH), 126.7 (q, J = 
30.0 Hz, CCF3), 127.5 (CH), 128.9 (C), 130.50 (4’’-CH), 130.8 (C), 132.0 (CH), 132.1 (CH), 139.1 
(C), 140.8 (C), 141.9 (C), 147.6 (5’’’-CH), 152.3 (C), 155.9 (C) ppm. MS (ESI): m/z (%) 480.17 
(M
+ 35
Cl+H, 100), 482.17 (M
+ 37
Cl+H, 30)Anal. Cald. for C21H13ClF3N3OS2: C 52.55, H 2.73, N 
8.76, S 13.36%; found C 52.24, H 2.74, N 8.62, S 13.27%. 
4.1.2.12. 1-Phenyl-3-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (5a): From compound 2c (100 
mg, 0.370 mmol) and phenylisocyanate (44.0 mg) compound 5a was isolated as a yellow solid (90.0 
mg, 65%). Mp 92-93 ºC. 
1
H NMR (DMSO-d6, 300 MHz): δ 6.73 (d, J = 5.2 Hz, 1H), 6.96-7.01 (m, 
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1H), 7.26-7.29 (m, 2H), 7.44-7.47 (m, 2H), 7.55-7.62 (m, 5H), 8.15 (d, J = 5.4 Hz, 1H), 8.51 (br s, 
1H), 8.77 (br s, 1H, NH), 9.02 (br s, NH) ppm. 
13
C NMR (DMSO-d6, 75.4 MHz): δ 115.1 (CH), 
118.4 (2×CH), 118.8 (C), 119.3 (2×CH), 122.2 (CH), 125.0 (CH), 128.8 (2×CH), 131.7 (CH), 136.2 
(2×CH), 139.4 (C), 141.9 (C), 143.8 (C), 147.4 (CH), 152.3 (C), 155.6 (C) ppm. MS (ESI- TOF) 
m/z (%): 378.07 (M
+
+H, 100). HRMS (ESI-TOF): calcd for C20H16N3OS2 [M
+
+H] 378.0729, found 
378.0720. Anal. Cald. for C20H15N3OS2: C 63.64, H 4.01, N 11.13, S 16.99%; found C 63.82, H 
4.15, N 10.92, S 16.59%. 
4.1.2.13. 1-(4-Methoxyphenyl)-3-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (5b): From 
compound 2c (60.0 mg, 0.230 mmol) and 4-methoxyphenylisocyanate (35.0 mg,) compound 5b was 
isolated as a yellow solid (65.0 mg, 70%). Mp.195-196ºC. 
1
H NMR (DMSO-d6, 400 MHz): δ 3.71 
(s, 3H, OMe), 6.72 (d, J = 5.2Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 
8.8 Hz, 2H), 7.58 (d, J = 5.6 Hz), 7.61 (d, J = 8.8 Hz, 2H), 8.14 (d, J = 5.6 Hz, 1H), 8.46 (d, J = 5.2 
Hz, 1H), 8.57 (br s, 1H, NH), 8.93 (br s, 1H, NH) ppm. 
13
 C NMR (DMSO-d6, 100.6 MHz): δ 55.2 
(OMe), 114.1 (2×CH), 114.9 (CH), 118.5 (C), 119.2 (2×CH), 120.2 (2×CH), 124.9 (CH), 129.4 (C), 
131.7 (CH), 132.3 (C), 136.2 (2×CH), 142.1 (C), 143.9 (C), 147.4 (CH), 152.5 (C), 154.7 (C), 155.7 
(C) ppm. MS (ESI- TOF) m/z (%): 408.08 (M
+
+H, 100). HRMS (ESI-TOF): calcd for C21H18N3O2S2 
[M
+
+H] 408.0835, found 408.0833. Anal. Cald. for C21H17N3O2S2: C 61.89, H 4.20, N 10.31, S 
15.74%; found C 62.01, H 3.94, N 10.60, S 15.32%. 
4.1.2.14. 1-(4-Cyanophenyl)-3-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (5c): From 
compound 2c (120 mg, 0.460 mmol) and 4-cyanophenylisocyanate (66.0 mg), compound 5c was 
isolated as a yellow solid (120 mg, 65%). Mp 154-155 ºC. 
1
H NMR (DMSO-d6, 400 MHz): δ 6.74 
(d, J = 5.2 Hz, 1H), 7.57 (d, J = 5.6 Hz, 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.63-7.65 (m, 4H), 7.74 (d, J 
= 8.8 Hz, 2H), 8.15 (d, J = 5.6 Hz, 1H), 8.47 (d, J = 5.2 Hz, 1H), 9.20 (br s, 1H, NH), 9.29 (br s, 1H, 
NH) ppm. 
13
C NMR (DMSO-d6, 100.6 MHz): δ 103.6 (C), 115.1 (CH), 118.2 (2×CH), 118.4 (C), 
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119.2 (C), 119.6 (2×CH), 125.0 (CH), 129.5 (C), 131.8 (CH), 133.3 (2×CH), 136.1 (2×CH), 141.2 
(C), 143.6 (C), 143.9 (C), 147.5 (CH), 151.9 (C), 155.7 (C) ppm. MS (ESI- TOF) m/z (%): 403.07 
(M
+
+H, 100) HRMS (ESI-TOF): calcd for C21H15N4OS2 [M
+
+H] 403.0682, found 403.0681. Anal. 
Cald. for C21H14N4OS2: C 62.67, H 3.51, N 13.92, S 15.93%; found C 62.85, H 3.73, N 13.57, S 
15.55%. 
4.1.2.15. 1-[3-(Trifluoromethyl)phenyl]-3-[4-(thieno[3,2b]pyridin-7-ylthio)phenyl]urea (5d): From 
4-(thieno[3,2-b]pyridine-7-ylthio)aniline (90.8 mg, 0.351 mmol) and 3-(trifluoromethyl)phenyl-
isocyanate (65.8 mg, 0.351 mmol, 48.4 µL) compound 5d was isolated as a colourless solid (86.0 
mg, 55%). Mp.162-164ºC. 
1
H NMR (DMSO-d6, 400 MHz): 6.74 (d, J = 4.8 Hz, 6’’’-H), 7.33 (br d, 
4’-H), 7.52 (apparent t, J = 8.0 Hz, 5’-H), 7.56-7.61 (m, 4H), 7,65 (d, J = 9.0 Hz, 2H), 8.01 (br s, 2’-
H), 8.15 (d, J = 5.6 Hz, 1H), 8.47 (d, J = 4.8 Hz, 5’’’-H), 9.13 (s, NH), 9.14 (s, NH). 13C NMR 
(DMSO-d6, 100.6 MHz): 114.3 (q, J = 4.0 Hz, 2’-CH), 115.1 (6’’’-CH), 118.4 (q, J = 4.0 Hz, 5’-
CH), 119.36 (C), 119.63 (2 CH), 122.0 (CH), 122.83 (C), 124.2 (q, J = 271.6 Hz, CF3), 125.0 (CH), 
129.5 (q, J = 31.2 Hz, CCF3), 129.6 (C), 130.0 (4’-CH), 131.8 (CH), 136.1 (2 CH), 140.3 (C), 141.5 
(C), 143.7 (C), 147.5 (5’’’-CH), 152.3 (C), 155.7 (C) ppm. MS (ESI) m/z (%): 446.25 (M++H, 100). 
Anal. Cald. for C21H14F3N3OS2: C 56.62, H 3.17, N 9.43, S 14.40%; found C 56.30, H 3.26, N 9.73, 
S 14.78%. 
4.1.2.16. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea 
(5e): From 4-(thieno[3,2-b]pyridine-7-ylthio)aniline (101.8mg, 0.394mmol) and 4-chloro-3-
(trifluoromethyl)phenyl-isocyanate (87.3mg, 0.394mmol) compound 5e was isolated as a light 
yellow solid (136 mg, 72%). Mp 224-226ºC. 
1
H NMR (DMSO-d6, 400 MHz): 6.74 (d, J = 4.8 Hz, 
6’’’-H), 7.56-7.66 (m, 7H), 8.1 (d, J = 2.4 Hz, 2’-H),  8.15 (d, J = 5.2 Hz, 1H), 8.47 (d, J = 4.8 Hz, 
5’’’-H), 9.18 (s, NH), 9.25 (s, NH). 13C NMR (DMSO-d6, 100.6 MHz): 115.1 (6’’’-CH), 117.0 (q, J 
= 6.0 Hz, 2’-CH), 119.7 (2×CH), 122.5 (C) 122.6 (C) 122.8 (q, J = 272.6 Hz, CF3), 123.3 (CH), 
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125.0 (CH), 126.7 (q, J = 30.2 Hz, CCF3), 129.5 (C), 131.8 (CH), 132.0 (CH), 136.1 (2×CH) 139.1 
(C), 141.3 (C), 143.6 (C), 147.4 (5’’’-CH), 152.2 (C), 155.7 (C) ppm. MS (ESI) m/z (%): 480.17 
(M
+ 35
Cl+H, 100), 482.17 (M
+ 37
Cl+H, 29). Anal. Cald. for C21H13ClF3N3OS2: C 52.55, H 2.73, N 
8.76, S 13.36%; found C 52.25, H 2.75, N 8.66, S 13.46%.  
 
4.2. VEGFR-2 kinase inhibition assay 
The compounds were assessed for VEGFR-2 inhibitory activity using the Z'-LYTE-Tyr1 Peptide 
assay kit (Invitrogen, Cat. PV3190) and according to the procedures recommended by the 
manufacturer.
12
 Briefly, assays were performed in a total of 20 µL in 384-well plates using 
fluorescence resonance energy transfer technology. A Tyr1 substrate (coumarin-fluorescein double-
labeled peptide) at 1 µM was incubated for 1 h with 4 µg/mL VEGFR-2, 10 μM ATP, and inhibitors 
at room temperature in 50 mM Hepes/NaOH (pH 7.5), 10 mM MgCl2, 2 mM MnCl2, 2.5mM DTT, 
0.10 mM orthovanadate, and 0.01% bovine serum albumin (BSA). Inhibitors were added to the 
wells with 4% DMSO added as solvent. The wells were incubated at 25 ºC for 1 h and 5 µL of 
development reagent was added to each well. After a second incubation of 1 h the stop reagent was 
added to each well. Using a Biotek FLX800 micro-plate the fluorescence was read at 445 nm and 
520 nm (excitation 400 nm), and Gen5™ Software was used for data analysis. The validation assay 
was performed using Staurosporine that present an IC50 value 6 nM that compares to the one 
reported in the literature.
16
 
 
4.3. Molecular docking protocol 
VEGFR-2 crystal structure (PDB: 3VHE) was extracted from the Protein Data Bank (PDB) 
(http://www.rcsb.org). The co-crystallized ligand was extracted from the PDB file, and 
AutoDockTools was used to assign polar hydrogens and Gasteiger charges. AutoGrid4 was used to 
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create affinity grid maps for all atom types. The affinity grids enclosed a volumetric space of 100 Å 
by 100 Å by 100 Å, with 0.375 Å spacing, centered on the coordinates x = 86.3, y = 51.2, z = 48.3. 
AutoDock4 (version 4.1) with the Lamarckian genetic algorithm was used with the following 
docking parameters: 100 docking runs, population size of 200, random starting position and 
conformation, translation step ranges of 2.0 Å, mutation rate of 0.02, crossover rate of 0.8, local 
search rate of 0.06, 2.5 and 25 million energy evaluations.
23
 Docked conformations were clustered 
using a tolerance of 2.0 Å RMSD. The entire virtual experiment was performed on a cluster of 64 
AMD 2.0 GHz processor, using software MOLA.
24 
The 3D compound-protein docking poses were 
analyzed manually using AutoDockTools, and Figure 1 was prepared using the software PyMOL.
18
 
 
4.4. Biological assays 
 
4.4.1. HUVECs Culture 
HUVECs were obtained from the Science Cell Research Labs (San Diego, CA, USA). HUVECs 
were harvested in gelatin-coated culture plates in M199 medium (Sigma-Aldrich, Sintra, Portugal) 
supplemented with 20% fetal bovine serum (FBS), 1% penicillin/ streptomycin (Invitrogen Life 
Technologies, Scotland, UK), 0.01% heparin (Sigma-Aldrich), and 30 mg/mL endothelial cell 
growth supplement (Biomedical Technologies Inc., MA, USA) and maintained at 37°C in a 
humidified atmosphere containing 5% CO2. The tested compounds were dissolved in DMSO and 
added to cell cultures at a concentration of 0.1-10 µM. Treatments were performed during 24 h in 
medium supplemented with 2% FBS, 1% penicillin/ streptomycin, and 60 ng/mL of the vascular 
endothelial growth factor (VEGF) (Sigma-Aldrich, Portugal). Control cells were treated with vehicle 
(0.1% DMSO). 
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4.4.2. HUVECs viability assay 
 HUVECs were seeded (2x10
5
 cells/mL) in 96-well plate, allowed to grow for 24 h and then 
incubated with different dilutions of tested compounds at a range concentration between 0.1 and 10 
µM or control (0.1% DMSO), in the presence of VEGF, for 24 h. After the incubation period, cells 
were washed with PBS and their viability was assessed using Cell Titer 96 Aqueous ONE Solution 
Reagent MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] colorimetric assay (Promega, Madison, USA), according to the instructions provided by 
the manufacturer and as previously described.
25
 Optical density was measured at 492 nm.  
4.4.3. HUVECs Proliferation assay 
 HUVECs (6x10
4
 cells/mL) were grown during 24 h and then incubated with compounds at 0.1-10 
µM or control (0.1% DMSO), in the presence of VEGF, for 24 h. Cells were also incubated with 5’-
bromodeoxyuridine (BrdU) solution at a final concentration of 0.01 mM during the treatment period. 
Optical density of proliferating cells (positive for BrdU) after ELISA assay using anti-BrdU-specific 
antibodies (Roche Diagnostics, Mannheim, Germany) was evaluated at the microplate reader 
according to the manufacturer’s instructions and as previously reported.26 Results were expressed as 
percentage of control (100%). 
4.4.4. HUVECs Migration assay: Wound-healing  
HUVECs were seeded in a 24-well plates pre-coated with 0.1% gelatin and were allowed to grow to 
100% confluence. Cell culture were injured by a 10 µL tip, cells were washed twice with PBS, and 
then incubated with fresh medium containing VEGF with or without the compounds in study at 
different concentrations for 24 h.  Cell migration to the damaged area was then visualized and 
photographed on a phase contrast microscope (Nikon) at a magnification of 100 .
25
 Inhibition 
percentage was expressed as percentage of the control (100%).  
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4.4.5 HUVECs Capillary-like Tube Formation assay 
Matrigel
®
 basement membrane matrix (growth factor reduced) (Corning, USA) was thawed at 4ºC, 
pipetted into pre-chilled 24-well plates (200µL matrigel/well) and incubated at 37ºC for 30 min. 
Then HUVECs (8x10
4
 cells/mL) were added to matrigel coated plates, followed by addition of 
various concentrations of compounds in study with VEGF (60ng/mL). After 24 h of incubation with 
5% CO2 at 37ºC, the number of capillary-like tube formation of each well was photographed using a 
phase-contrast microscope (Nikon, UK) at 100 x magnifications. Tube formation was quantitated by 
manual counting the number of branch points.
25
 All experiments were done in triplicate. Inhibition 
percentage was expressed as percentage of control (100%).  
4.4.6. Western Blotting Analysis 
 In brief, proteins were isolated from HUVEC lysates using RIPA (Chemicon International, CA, 
USA) and 20 µg of protein were separated by 8% SDS-PAGE and transferred to Hybond 
nitrocellulose membrane (Amersham, Arlington, VA, USA). Membranes were then incubated with 
primary antibodies including phosphorylated (activated) VEGFR-2 (Santa Cruz Biotechnology, CA, 
USA), total VEGFR-2 (Cell Signalling, MA, USA) and β-actin (Abcam, Cambridge, UK). After 
overnight incubation at 4°C, membranes were washed with TBST and incubated with secondary 
antibodies at room temperature for 1 h. Immunoreactive bands were then visualized by the enhanced 
chemiluminescence detection system (ECL kit, Amersham, Arlington, USA).
26
    
4.4.7. Statistical Analyses 
 All experiments were performed at least in three independent experiments. Data are expressed as 
mean ± SEM. The significance of the differences between the means observed was evaluated using 
the one-way ANOVA followed by Bonferroni test. p < 0.05 was considered statistically significant. 
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